MAZEMaze Therapeutics, Inc.

MAZE Stock Price, Valuation & Chart | Maze Therapeutics, Inc.

Compare

$26.720+0.19 (+0.72%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology MAZE intrinsic value MAZE calculated fair value vs price

Overview Financials Dividends Ratios

MAZE Historical price chart

MAZE Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization1.48B

PE Ratio-10.56

EPS-2.53

Trading Volume440.70K

Today's High/Low27.18/26.0

Dividend Yield0.00

52 Week High/Low53.65/14.16

Shares Outstanding55.35M

MAZE Financial Statement

MAZE Analyst ratings

MAZE Analysis & performance metrics

MAZE Company profile

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic…

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1…

MAZE Management team

Name

Position

Courtney J. Phillips J.D.

General Counsel & Corporate Secretary

Amy BachrodtCFO

Senior Vice President of Finance & Chief Financial Officer

Nazila Habibizad

Senior Vice President of Technical Operations & Supply Chain

Jason V. Coloma M.B.A., M.P.H., Ph.D.CEO

Chief Executive Officer & Director

Vipin Vijayakumar

Vice President of R&D Infrastructure and Operations

Maarten Hoek

Senior Vice President of Research

Winston Tse

Senior Vice President of Drug Discovery

Atul Dandekar

Chief Strategy & Business Officer

Name

Position

Courtney J. Phillips J.D.

General Counsel & Corporate Secretary

Amy BachrodtCFO

Senior Vice President of Finance & Chief Financial Officer

Nazila Habibizad

Senior Vice President of Technical Operations & Supply Chain

Jason V. Coloma M.B.A., M.P.H., Ph.D.CEO

Chief Executive Officer & Director

Vipin Vijayakumar

Vice President of R&D Infrastructure and Operations

Maarten Hoek

Senior Vice President of Research

Winston Tse

Senior Vice President of Drug Discovery

Atul Dandekar

Chief Strategy & Business Officer

Management Team

Courtney J. Phillips J.D.

General Counsel & Corporate Secretary

Amy BachrodtCFO

Senior Vice President of Finance & Chief Financial Officer

Nazila Habibizad

Senior Vice President of Technical Operations & Supply Chain

Jason V. Coloma M.B.A., M.P.H., Ph.D.CEO

Chief Executive Officer & Director

Vipin Vijayakumar

Vice President of R&D Infrastructure and Operations

Maarten Hoek

Senior Vice President of Research

Winston Tse

Senior Vice President of Drug Discovery

Atul Dandekar

Chief Strategy & Business Officer

Management

Courtney J. Phillips J.D.

General Counsel & Corporate Secretary

Amy BachrodtCFO

Senior Vice President of Finance & Chief Financial Officer

Nazila Habibizad

Senior Vice President of Technical Operations & Supply Chain

Jason V. Coloma M.B.A., M.P.H., Ph.D.CEO

Chief Executive Officer & Director

Vipin Vijayakumar

Vice President of R&D Infrastructure and Operations

Maarten Hoek

Senior Vice President of Research

Winston Tse

Senior Vice President of Drug Discovery

Atul Dandekar

Chief Strategy & Business Officer

Total 8 executives

MAZE Frequently asked questions

What is Maze Therapeutics, Inc. (MAZE) Stock Price?

Current stock price of Maze Therapeutics, Inc. (MAZE) stock is $26.720. The stock price is +0.72% higher in the session. The intraday range can be seen from this page. Volume of Maze Therapeutics, Inc. (MAZE) stock is 440.70K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Maze Therapeutics, Inc. (MAZE) stock price going up or down today?

The stock price of Maze Therapeutics, Inc. (MAZE) can change with earnings, company news, and overall market sentiment. Maze Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Maze Therapeutics, Inc. stock expensive at its current price?

Whether Maze Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for MAZE on this page is -10.56. EPS on this page is -2.53. Compare those figures with peers and growth expectations before deciding if the current Maze Therapeutics, Inc. price is justified.

How has the stock price of Maze Therapeutics, Inc. (MAZE) performed historically?

Historical performance for Maze Therapeutics, Inc. (MAZE) is shown on the price chart on this page. Review multi-period moves alongside volume to see how MAZE reacted to past earnings and market events.

Should I buy Maze Therapeutics, Inc. (MAZE) stock, at this price?

Buying Maze Therapeutics, Inc. (MAZE) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.